Table 2 The extracted antidiabetic medication prescription data obtained in the second repeated cross-sectional study
Year | 2001 | 2005 | 2010 | 2013 | rs# | p value# |
|---|---|---|---|---|---|---|
n | 14,996 | 13,976 | 17,561 | 3118 | ||
Sulfonylureas (%) | 5102 (34) | 4016 (29) | 5142 (29) | 896 (29) | <0.01* | |
Glimepiride (n) | 197 | 2414 | 4399 | 783 | ||
Glimepiride (mg) | 3 (2, 4) [0.5, 6] | 2 (1, 3) [0.5, 6] | 1 (0.5, 2) [0.5, 6] | 1 (0.5, 1.5) [0.5, 6] | −0.38 | <0.01 |
Biguanide (%) | 3194 (21) | 3633 (26) | 5432 (31) | 1050 (34) | <0.01* | |
Metformin (n) | 3 164 | 3 622 | 5 430 | 1 050 | ||
Metformin (mg) | 750 (750, 750) [250, 1000] | 750 (750, 750) [250, 1000] | 750 (750, 750) [250, 1500] | 750 (750, 1500) [250, 2250] | 0.36 | <0.01 |
Thiazolidine (%) | 338 (2) | 1907 (14) | 6983 (40) | 758 (24) | <0.01* | |
Pioglitazone (mg) | 30 (30, 30) [15, 60] | 15 (15, 30) [7.5, 30] | 15 (15, 30) [7.5, 45] | 15 (15, 30) [7.5, 45] | 0.01 | 0.01 |
α-GI (%) | 2936 (20) | 2696 (19) | 3966 (23) | 561 (18) | <0.01* | |
Voglibose (n) | 2351 | 2394 | 3390 | 493 | ||
Voglibose (mg) | 0.6 (0.6, 0.9) [0.2, 0.9] | 0.6 (0.6, 0.9) [0.2, 0.9] | 0.9 (0.6, 0.9) [0.2, 0.9] | 0.9 (0.6, 0.9) [0.3, 0.9] | 0.30 | <0.01 |
Meglitinides (%) | 654 (4) | 1352 (10) | 1418 (8) | 155 (5) | 0.45* | |
Nateglinide (n) | 654 | 1275 | 1170 | 127 | ||
Nateglinide (mg) | 270 (270, 270) [60, 360] | 270 (180, 270) [30, 360] | 270 (180, 270) [30, 360] | 270 (120, 270) [60, 360] | −0.04 | <0.01 |
DPP4I (%) | 0 (0) | 0 (0) | 361 (2) | 1176 (38) | <0.01* | |
Sitagliptin (n) | 0 | 0 | 361 | 818 | ||
Sitagliptin (mg) | 50 (50, 50) [25, 100] | 50 (25, 50) [25, 100] | 0.10 | <0.01 | ||
Insulins (%) | 3550 (24) | 5085 (36) | 5660 (32) | 990 (32) | <0.01* |